A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
Latest Information Update: 02 Aug 2023
At a glance
- Drugs Atezolizumab (Primary) ; Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms ATEZOGIST
- 28 Apr 2022 Planned primary completion date changed from 1 Dec 2025 to 1 Jan 2025.
- 28 Apr 2022 Status changed from not yet recruiting to recruiting.
- 16 Dec 2021 New trial record